Glenmark Pharmaceuticals Q4 Results
- BSE: 532296
- NSE: GLENMARK
- ISIN: INE935A01035
- Sector: Biotechnology & Drugs
BSE
2,166.65
-14.80 (-0.68%)
-14.80 (-0.68%)Volume45.44 K
Updated: Fri 5 Jun, 2026 | 15:25:38
NSE
2,166.20-14.40 (-0.66%)
-14.40 (-0.66%)Volume5.13 L
Updated: Fri 5 Jun, 2026 | 15:50:17
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹3,770.59 Cr.(15.80%)
- Operating Profit₹241.29 Cr.(282.99%)
- Profit After Tax₹301.41 Cr.(6382.02%)
- Operating Margin6.40%(230.74%)
Note: Comparison is on YoY basis
Quarterly - Glenmark Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 3,529.30 | 3,369.65 | 4.74% | 3,156.73 | 10.53% |
| Depreciation/ Amortization | 147.91 | 154.45 | -4.23% | 151.34 | 18.13% |
| Operating Income | 241.29 | 530.97 | -54.56% | -93.78 | 282.99% |
| Net Income | 301.41 | 403.21 | -25.25% | -1,218.28 | 6382.02% |
| Other Operating Expenses Total | 948.27 | 894.37 | 6.03% | 862.13 | 9.04% |
| Net Income Before Taxes | 387.77 | 534.00 | -27.38% | 530.83 | 4762.90% |
| Total Revenue | 3,770.59 | 3,900.62 | -3.33% | 3,062.95 | 15.80% |
| Selling/ General/ Admin Expenses Total | 887.44 | 841.40 | 5.47% | 700.95 | 20.48% |
| Diluted Normalized EPS | 20.96 | 19.21 | 9.12% | -33.78 | 182.23% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.